NCT06348797View on ClinicalTrials.gov

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
DRUG

α-PD-L1/4-1BB DLL3 CAR-T (BHP01)

Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses; Bridge radiotherapy with 15 Gray (Gy)/5 fractions; α-PD-L1/4-1BB DLL3 CAR-T (BHP01): the first dose was 5x10\^5/kg.

Trial Locations (1)

610041

RECRUITING

West China Hospital Sichuan University, Chengdu

All Listed Sponsors
collaborator

Chengdu Brilliant Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan University

OTHER